The consultation usually goes well. Someone in a clean office on the Upper East Side or in Flatiron explains that your knee, or your shoulder, or your face, or your general sense of running out of road, can be addressed by putting regenerative cells back where they are needed. There is a diagram. There is a number. The number is between two thousand and twenty thousand dollars, and it is almost never covered by anything.
Most people walk out of that room genuinely unsure what they were just offered. Not because they are not smart. Because the word regenerative is doing an enormous amount of work and explaining almost nothing.
This piece is an attempt to take that category apart calmly. What is actually in the syringe, what the strongest human data says, what the regulatory situation is in the United States right now, and where a systemic approach like hyperbaric oxygen therapy sits in relation to all of it. No villains. Just mechanism, evidence, and money.
Regenerative Is a Marketing Category, Not a Mechanism
Three very different things get sold under one banner in New York.
Platelet rich plasma, usually called PRP, is your own blood, spun down so the platelet fraction is concentrated, then injected back. Platelets carry growth factors. The logic is that concentrating them at an injury site accelerates repair.
Stem cell products vary enormously. Some are your own cells, taken from fat or bone marrow and reinjected the same day. Others are purchased products derived from umbilical cord or amniotic tissue, which often contain very few living cells by the time they are thawed and injected.
Exosomes are not cells at all. They are tiny vesicles released by cells, carrying proteins and genetic material that influence other cells. The pitch is that you get the signaling without the cells.
These three have different mechanisms, different evidence bases, and different legal standing. Grouping them together is convenient for selling and useless for deciding. The first honest step is separating them.
What the Strongest Human Data Says About PRP
PRP has the most and the best clinical research of the three, which makes it the most informative place to look.
The largest and most rigorous trial is worth sitting with. In RESTORE, 288 adults with mild to moderate knee osteoarthritis were randomized to receive either PRP injections or saline. Neither the participants nor the injecting physicians knew which. At twelve months, there was no significant difference between the groups in pain or in medial tibial cartilage volume (Bennell et al., JAMA, 2021, doi:10.1001/jama.2021.19415). The authors concluded the findings do not support PRP use for knee osteoarthritis.
That is not a small or hostile study. It is a large, well designed, placebo controlled trial published in one of the most scrutinized journals in medicine.
There are other trials with more positive results, and PRP advocates point to differences in platelet concentration and preparation method as the reason. That argument is not unreasonable, and it may turn out to be right. But it is also the shape of argument that appears whenever a strong null result arrives, and the honest reading is that PRP for knee osteoarthritis is contested, not established. If you want to work through that kind of conflicting literature yourself, we wrote a guide to reading a hyperbaric oxygen study without being misled, and the same tools apply to any field.
Worth noting plainly: PRP is your own blood, so the safety profile is reasonable. The question is efficacy and price, not danger.
The Part About Exosomes That Rarely Comes Up in the Consultation
Here is a fact that is easy to verify and almost never volunteered.
There are no FDA approved exosome products in the United States, for any use. The agency issued a public safety notification in December 2019 after several patients in Nebraska experienced serious adverse events following injection with products marketed as containing exosomes, and it has repeated the point since: clinics claiming these products fall outside drug and biologic regulation are incorrect. Warning letters to manufacturers have continued in the years since.
This does not mean exosome science is fake. The underlying biology is real and the research is moving. It means the product being sold to you in a New York office today is an unapproved biologic, nobody is independently verifying what is in the vial, and the gap between the research and the storefront is wider than the brochure suggests.
Similar reasoning applies to many purchased stem cell products. A vial that has been frozen, shipped, and thawed often contains few viable cells. You are frequently paying cell prices for something closer to a protein soup.
The reasonable question to ask in any consultation is simple: what exactly is in this, who made it, and under what approval. A good provider will answer directly. The answer you get tells you a great deal.
Your Body Already Makes These Cells
There is a step in this conversation that almost always gets skipped, and it is the interesting one.
You have stem and progenitor cells. They live in your bone marrow and they mobilize into circulation under certain conditions. The entire premise of the injection model is that you do not have enough of them in the right place. That premise is worth examining before spending five figures on it.
Hyperbaric Oxygen Therapy is a systemic modality that influences the human body on cellular and physiological level.
Researchers at the University of Pennsylvania measured what happens to circulating stem cells under pressurized oxygen. In human subjects, a single two hour exposure at 2.0 ATA doubled circulating CD34 positive cells. Across twenty sessions, those cells rose roughly eightfold, while overall white cell count did not meaningfully change. The effect ran through a nitric oxide dependent pathway, and it disappeared in mice engineered without the relevant enzyme (Thom et al., American Journal of Physiology Heart and Circulatory Physiology, 2006, doi:10.1152/ajpheart.00888.2005).
That is your own marrow, responding to a repeated environmental signal, releasing your own cells into your own circulation. No vial, no supplier, no question about what is in it.
The honest limits matter here too. Mobilizing cells into the bloodstream is not the same as proving those cells arrive at a specific damaged knee and rebuild cartilage. That chain has not been demonstrated end to end in humans, and anyone telling you otherwise is ahead of the data. What the research shows is a measurable, repeatable physiological response. What it does not show is a known destination.
Terrain Versus Delivery
The cleanest way to hold all of this is a distinction between delivery and terrain.
The injection model is a delivery model. It assumes the missing ingredient is material, and that placing material at a site solves the problem. Sometimes that is right. For a specific structural defect in a specific location, delivery makes sense.
The terrain model asks a different question. If tissue in that area is inflamed, poorly perfused, and metabolically strained, material arriving there lands in an environment that cannot do much with it. Correcting the supply does not help if the conditions for repair are absent.
This is why framing HBOT as a competitor to regenerative injections misses the point. It is not aiming at the same thing. Pressurized oxygen changes systemic conditions, including perfusion and inflammatory signaling, across the whole body rather than at one location. That is also why its effects show up in the places you would expect from a terrain intervention. In a double blind sham controlled trial, master athletes completing forty sessions showed improved maximal oxygen uptake alongside muscle biopsy evidence of greater mitochondrial respiration and mass, measured afterward while breathing ordinary air (Hadanny et al., Sports Medicine Open, 2022, doi:10.1186/s40798-021-00403-w). The caveats are real: roughly thirty athletes completed it and several authors have commercial hyperbaric ties. It needs replication.
For people whose main complaint is systemic rather than structural, this distinction is the whole conversation. We covered that territory in post viral and chronic fatigue in NYC, and in how tissue repair and muscle quality behave when the underlying conditions shift. For athletes weighing recovery inputs against each other, marathon and endurance recovery covers the same reasoning applied to training load.
The Money Side
New York prices this market aggressively, so the arithmetic is worth doing out loud.
PRP in the city generally runs eight hundred to two thousand dollars per injection, often sold in a series. Exosome injections commonly run two thousand to six thousand. Stem cell packages regularly reach five thousand to twenty thousand, and sometimes beyond. Almost none of this is reimbursed by anything.
Private hyperbaric sessions in New York City generally run four hundred to six hundred dollars, and meaningful protocols are measured in dozens of sessions rather than single visits. That is also serious money, and it should be weighed seriously.
The comparison that matters is not the headline number. It is what the number buys in terms of evidence quality. A single exosome injection at four thousand dollars buys you a product with zero approved versions and no independent verification of contents. A forty session hyperbaric course buys you an exposure with blinded sham controlled trials behind it, honest uncertainty included, and a mechanism that does not depend on a supplier.
Neither is a small decision. But one of them lets you know exactly what you are getting. Pressure and oxygen are measurable, which is incidentally why the difference between a hard chamber and a soft one changes what you receive and is worth understanding before you book anything anywhere.
What a Reasonable Order of Operations Looks Like
If you have a specific structural problem, a torn thing in a known location, an orthopedic opinion comes first. That is a delivery question and it belongs with someone who can image it.
If what you are describing is diffuse, if it is fatigue and poor recovery and a body that has stopped bouncing back, no injection into one joint addresses that, regardless of price.
And if you are going to do regenerative work, the environment it lands in is not a side detail. Supporting systemic conditions before and around an intervention is a reasonable sequence, and it is the same logic we applied to heat, cold, and how HBOT fits into a real recovery stack.
What this city sells extremely well is urgency. What it sells badly is sequence. Knowing the order things belong in is worth more than any individual item on the menu, and it tends to be the difference between spending money and getting your life back.
Frequently Asked Questions
-
No, and it is not aiming at the same thing. Injections place material at a site. Hyperbaric oxygen changes systemic conditions across the body. They answer different questions, and for some people the useful one is the systemic question.
-
Research measuring circulating CD34 positive cells found they doubled after a single session and rose roughly eightfold across twenty sessions. What that does not establish is where those cells end up or what they rebuild. The measurement is solid, the downstream chain is not fully mapped.
-
No. There are currently no FDA approved exosome products in the United States for any use, and the agency has issued public safety notifications and warning letters on this point.
-
The largest placebo controlled trial, with 288 participants, found no significant benefit over saline at twelve months. Other smaller trials are more favorable. It is contested rather than settled, and worth discussing honestly with whoever is offering it.
-
There is no mechanistic conflict, and supporting the environment that tissue repair happens in is a reasonable thing to do alongside other approaches. Timing should be individualized rather than standardized.
-
Because the market tolerates it. Pricing in this category tracks what people will pay for hope more than it tracks production cost or evidence strength, which is exactly why asking what is in the vial is a useful question.
-
Halcyon Life provides hyperbaric oxygen therapy in New York City in a hard chamber with scheduled air breaks in every session. We will tell you plainly when your situation calls for something else first, including when that something else is not us.
